newsfilter
← Latest News
GlobeNewswire·

Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...